Clinical effect of alprostadil combined with Shuxuetong on chronic obstructive pulmonary disease complicated with pulmonary hypertension

doi:10.3969/j.issn.1674-3806.2019.01.20

Abstract：Objective To explore the clinical effect of alprostadil combined with Shuxuetong on chronic obstructive pulmonary disease (COPD) complicated with pulmonary hypertension (PH).MethodsOne hundred and seventy-two patients with COPD complicated with PH were selected and were randomly divided into control group, group A, group B and group C, with 43 cases in each group.All of the groups were given conventional treatment.Group A was treated with alprostadil.Group B was treated with Shuxuetong, and group C was treated with alprostadil plus Shuxuetong.The levels of serum endothelin-1 (ET-1), nitric oxide (NO), fibrinogen (FIB) and D-dimer (DD) were detected before treatment and 2 weeks after treatment, and the pulmonary function, average pulmonary artery pressure (m PAP) and clinical effects were assessed.Results The FEV1/FVC (％) [ (64.86±1.16) ％]and SGRQ scores[ (79.27±4.09) points]in group C were significantly higher than those in the other 3 groups (P＜0.05).The m PAP of group C[ (30.15±1.88) mm Hg]was lower than those of the other 3 groups (P＜0.05).After treatment, the levels of ET-1[ (51.70±7.14) ng/L], FIB[ (3.51±0.37) g/L], and DD[ (140.35±9.67) mg/L]in group C were lower than those in the other 3 groups (P＜0.05).After treatment, the concentration of blood NO in group C[ (40.56±3.71) μmol/L]was higher than those in the other 3 groups (P＜0.05).ConclusionAlprostadil combined with Shuxuetong can significantly improve the lung function, reduce the pulmonary arterial pressure, and improve the endothelium cell and coagulation status in the patients with COPD complicated with PH.